Introduction: Many new markers are now available as an aid for decisions about prostate biopsy for men without prostate cancer and/or to improve risk stratification for men with newly diagnosed prostate cancer.
Approximately 1.1 million men were diagnosed with prostate cancer globally in 2012 with an estimated 307,000 deaths. 1 In the United States an estimated 180,890 men were diagnosed with prostate cancer in 2016 along with 26,120 deaths. 2 There is strong evidence that early detection and curative treatment improve outcomes for men with clinically significant prostate cancer, but many prostate cancers have a prolonged natural history and are not destined to cause harm during a man's lifetime. Identifying which cancers are destined to progress and would benefit from early radical treatment is one of the most critical questions in urologic oncology.
Markers for Prostate Biopsy
The majority of prostate cancer is diagnosed through PSA based screening. Historically, decisions about prostate biopsy were based on a single threshold PSA value, as was the case in the major randomized trials of PSA screening. For example, the ERSPC (European Randomized Study of Screening for Prostate Cancer) primarily used a threshold of 3 ng/ml to recommend biopsy and the U.S. PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial used a cutoff of 4 ng/ml. 3, 4 However, data from empiric prostate biopsies in the PCPT (Prostate Cancer Prevention Trial) showed that there is no single PSA threshold that can reliably exclude prostate cancer or high grade disease. 5 Furthermore, many nonmalignant conditions and other exposures can influence PSA levels, ranging from body mass index to various medications and benign disorders of the urinary tract. The limited specificity of PSA testing leads to unnecessary biopsies with associated risks, including an increasing risk of infectious complications. 6 Further downstream, PSA screening also causes harm by leading to the detection of indolent tumors. Several options have been proposed to aid in prostate biopsy decisions and reduce downstream harms. One simple method to avoid unnecessary prostate biopsy is to repeat an abnormal PSA measurement. A recent study from the Ottawa Regional Prostate Cancer Assessment Center examined the usefulness of repeating the PSA test within 3 months for men with levels of 4 to 10 ng/ml. 7 Overall 25%
of the men had a normal result (defined as a PSA less than 4 ng/ml) on repeat testing. These men were significantly less likely to undergo a prostate biopsy or to be diagnosed with prostate cancer. Of note, the same laboratory should be used for repeat PSA measurements when possible due to differences in measured PSA between assays, which could result in pseudo-acceleration or pseudo-deceleration.
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There are also several variations on the use of PSA that can improve specificity, such as applying different thresholds based on age.
9 For example, Oesterling et al recommended thresholds of 2.5, 3.5, 4.5 and 6.5 ng/ml in men in their 40s, 50s, 60s and 70s, respectively, as a means of improving specificity. 9 More recently, the American Urological Association encouraged increasing the threshold for biopsy to 10 ng/ml for men older than 70 years who choose to continue screening 10 based on data from the PIVOT (Prostate Cancer Intervention versus Observation Trial) randomized trial.
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Changes in PSA with time, or PSA velocity, is another way to increase the specificity of PSA for prostate cancer. 12 Although PSA does increase with age and benign prostatic hyperplasia, these changes are typically insidious. For example, in a trial of men with moderately to severely symptomatic benign prostatic hyperplasia the average PSA velocity was 0.15 ng/ml per year. 13 A PSAV greater than 0.4 ng/ml per year is a significant predictor of prostate cancer risk 14 and higher PSA velocity (greater than 2 ng/ml per year)
has been associated with life threatening prostate cancer. 15 However, there are several limitations to PSAV. A high PSA velocity (greater than 3 ng/ml per year) may represent prostatitis so the clinical history and context are important for the proper interpretation of PSA trends. 16 Also, an adequate PSA history is necessary to calculate PSAV and it is not informative with an insufficient number or frequency of tests (less than 3 tests or interval greater than 2 years between the tests). 17 An alternate method of evaluating changes in PSA over time is the PSA velocity risk count, proposed by Carter et al in 2007 . 18 This involves calculating the number of times in a row that PSAV exceeds 0.4 ng/ml per year as a way of evaluating for sustained increases. In a large validation study men with a risk count of 2 (meaning 2 successive PSAV measurements greater than 0.4 ng/ml per year) had a significantly greater risk of high grade prostate cancer, and the PSAV risk count provided an incremental predictive value above PSA and age alone. 19 Another option is to divide PSA by volume to calculate PSA density, which is a robust predictor of significant prostate cancer. 20 For men who underwent prostate imaging before biopsy (such as those undergoing repeat biopsy or biopsy naïve men who underwent MRI), PSA density can be readily calculated. For men undergoing initial biopsy without previous imaging, even a broad, categorical estimation of prostate volume from DRE can be incorporated with other clinical variables into a nomogram for risk stratification. 21 The specificity of PSA based screening could also be improved by determining the amount of PSA that is circulating complexed to proteins (complexed PSA) versus the unbound or "free" form (percent free PSA). 22 For men with a total PSA greater than 3 ng/ml the 2016 NCCN Ò Guidelines state that percent free PSA is potentially informative regarding the need for initial or repeat prostate biopsy. 23 A lower percent free PSA also predicts a higher risk of aggressive prostate cancer. 24 Two other PSA based marker tests offered in the 2016 NCCN guidelines for initial and repeat biopsy decisions are the Prostate Health Index and the 4Kscore. 23 phi is a blood test that uses a mathematical calculation to weigh the concentration of total, free and [À2]pro-PSA. 25 Large prospective studies globally have shown that phi outperforms PSA and free PSA for the prediction of prostate biopsy outcome. 25, 26 Numerous studies have consistently shown that phi is more specific for clinically significant disease compared to its individual components. 27 43, 44 Therefore, the results of ConfirmMDx may also be used to help decide on repeat prostate biopsy. Similar to imaging, ConfirmMDx has the added advantage of providing some information on localization so that additional sampling can be targeted at the region with hypermethylation. Finally, mpMRI is increasingly being used for prostate cancer localization and targeted prostate biopsy. In a recent systematic review Futterer et al reported that mpMRI had a negative predictive value of 63% to 98% for clinically significant prostate cancer. 45 More data are needed on the effectiveness and costs of combining markers and imaging for prostate cancer detection.
Biomarkers for Prostate Cancer Staging
Traditionally PSA, clinical stage and biopsy Gleason score were the main parameters used for prognostication and prostate cancer management decisions. These 3 variables form the basis of the D'Amico risk classification scheme, Partin tables and Kattan nomograms. 46e48 Many other nomograms have been developed incorporating other clinical and pathological variables, such as the CAPRA (Cancer of the Prostate Risk Assessment) score, which also includes age and percent positive biopsy cores. 49 All of these tools have been used as an aid for patients with newly diagnosed prostate cancer making decisions about treatment. The identification and commercialization of several new markers have raised the possibility of performing risk stratification with greater precision. One such test is the Prostate Health Index, a blood test combining total, free and [À2]pro-PSA, 25 as previously described. In addition to its established role in prostate biopsy decisions for at risk men, phi has also been evaluated in men diagnosed with prostate cancer. Independent studies from the United States and Japan of men on active surveillance showed that phi measurements at baseline predicted subsequent progression. 50, 51 In the Johns Hopkins program longitudinal measurements of phi during active surveillance also predicted subsequent biopsy reclassification. 50 phi has also been shown to predict adverse pathology and biochemical recurrence among men undergoing radical prostatectomy. 52e54 These results confirm a role for phi in risk stratification and decisions about the need for interventional management in prostate cancer cases. Similarly, the 4Kscore has been shown to predict the presence of significant prostate cancer at surgery. 55 It has also been shown to predict the long-term risk of metastatic disease, 56 suggesting that the pre-diagnostic value can be used to help inform decisions about treatment for newly diagnosed patients. The PCA3 urinary test has also been evaluated in groups of men diagnosed with prostate cancer. Several studies have evaluated PCA3 as a predictor of pathology features at radical prostatectomy with conflicting results. Nakanishi et al found a direct relationship between PCA3 scores and tumor volume at prostatectomy, and that PCA3 results could be used to predict small volume disease. 57 Other studies have similarly found that PCA3 could be used to predict insignificant disease. 58 In contrast, there are also multiple reports of no association between PCA3 and adverse tumor features, 59 and it was not an independent predictor of short-term biopsy progression during active surveillance. 60 Several tissue tests have recently been reviewed and are available as an aid to risk stratification in men with a prostate cancer diagnosis. 61 The 2016 NCCN guidelines state that tumor based molecular tests may be considered by men with clinically localized disease. The ProlarisÒ test examines a panel of cell cycle progression genes and has been shown to predict 10-year prostate cancer specific mortality among men undergoing conservative management. 62 Another genomic tissue test, Oncotype DXÒ, examines several different gene pathways involved in prostate cancer and can be used to improve the prediction of adverse pathology at prostatectomy. 63 Finally, DecipherÒ is a panel of 22 RNA expression markers previously shown to predict metastasis after prostatectomy, and which can also be measured in biopsy specimens. 64 All of these tests are commercially available to assist in initial treatment selection. However, they are expensive and data on long-term comparative effectiveness are currently lacking. Finally, mpMRI may also be used for staging in men with newly diagnosed prostate cancer and can predict the risk of adverse features at prostatectomy. The NICE (National Institute for Health and Care Excellence) guidelines in the UK have already incorporated up-front MRI for men considering active surveillance, 65 although this has not yet been formally incorporated into surveillance guidelines elsewhere. Additional study is needed on the use of serial MRI during active surveillance to predict progression, 66 and how to combine this with other noninvasive markers as a potential way of reducing the frequency of repeat biopsy. benefit from early detection, withholding biopsy in men at low risk for clinically significant prostate cancer, and withholding treatment in men at low risk for disease progression and mortality. Broadly speaking, these are issues of a test's specificity, ie the ability of the test to exclude patients without significant disease. As highlighted in this article, low specificity is the major shortcoming of PSA. Using PSA threshold as the criterion for biopsy, we biopsy far too many men, exposing those without clinically significant prostate cancer to the harms of biopsy, over detection and overtreatment. Other phases of diagnosis and management are similarly affected by the low specificity of traditional tests.
Reliance on the specificity of a test demands that the test reliably exclude patients without significant prostate cancer. This article describes the availability and utility of biomarkers at each phase of diagnosis and treatment. It drives home the point that we are moving toward a more sophisticated paradigm for detection and management, one in which specificity is enhanced by more refined risk stratification tools, thereby minimizing harms associated with diagnosis and management. Improvements in biomarkers and imaging, combined with implementation efforts that include shared decision making, will improve the risk-to-benefit ratio of screening, thereby improving care and strengthening the case for reevaluation of current screening guidelines.
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